​

Disc Medicine (IRON) Stock Forecast, Price Target & Predictions

OverviewFinancialsChart

IRON Stock Forecast

Disc Medicine stock forecast is as follows: an average price target of $77.67 (represents a 20.42% upside from IRON’s last price of $64.50) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.

IRON Price Target

The average price target for Disc Medicine (IRON) is $77.67 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $112.00 to $50.00. This represents a potential 20.42% upside from IRON's last price of $64.50.

IRON Analyst Ratings

Buy

According to 12 Wall Street analysts, Disc Medicine's rating consensus is 'Buy'. The analyst rating breakdown for IRON stock is 0 'Strong Buy' (0.00%), 11 'Buy' (91.67%), 0 'Hold' (0.00%), 1 'Sell' (8.33%), and 0 'Strong Sell' (0.00%).

Disc Medicine Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2024Greg HarrisonScotiabank$70.00$64.788.06%8.53%
Nov 05, 2024Evan David SeigermanBMO Capital$112.00$63.2477.10%73.64%
Oct 23, 2024Roger SongJefferies$89.00$50.9274.78%37.98%
Sep 16, 2024Douglas TsaoH.C. Wainwright$70.00$47.7946.47%8.53%
Aug 22, 2024Tiago FauthWells Fargo$75.00$49.3152.10%16.28%
Aug 08, 2024Danielle BrillRaymond James$50.00$42.8516.69%-22.48%
Jun 17, 2024Evan David SeigermanBMO Capital$70.00$45.8052.84%8.53%
May 10, 2024Danielle BrillRaymond James$43.00$29.9543.57%-33.33%
Apr 02, 2024Evan David SeigermanBMO Capital$50.00$34.2146.16%-22.48%
Apr 01, 2024Ben BurnettStifel Nicolaus$71.00$34.21107.54%10.08%
Apr 01, 2024David NierengartenWedbush$43.00$32.0034.38%-33.33%
Apr 01, 2024Danielle BrillRaymond James$40.00$29.4036.05%-37.98%

The latest Disc Medicine stock forecast, released on Nov 05, 2024 by Greg Harrison from Scotiabank, set a price target of $70.00, which represents a 8.06% increase from the stock price at the time of the forecast ($64.78), and a 8.53% increase from IRON last price ($64.50).

Disc Medicine Price Target by Period

1M3M12M
# Anlaysts-312
Avg Price Target-$90.33$65.25
Last Closing Price$64.50$64.50$64.50
Upside/Downside-100.00%40.05%1.16%

In the current month, the average price target of Disc Medicine stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Disc Medicine's last price of $64.50. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 05, 2024ScotiabankSector OutperformSector OutperformHold
Oct 23, 2024JefferiesBuyInitialise
Oct 16, 2024ScotiabankOutperformInitialise
Sep 16, 2024H.C. WainwrightBuyBuyHold
Aug 22, 2024Wells FargoOverweightInitialise
Aug 08, 2024Raymond JamesOutperformOutperformHold
Jun 14, 2024WedbushOutperformOutperformHold
Jun 13, 2024BMO CapitalOutperformOutperformHold
May 10, 2024Raymond JamesOutperformOutperformHold
Apr 02, 2024BMO CapitalOutperformOutperformHold
Apr 01, 2024WedbushOutperformOutperformHold
Apr 01, 2024Raymond JamesStrong BuyOutperformDowngrade
Jun 09, 2023Raymond JamesStrong BuyUpgrade
Feb 28, 2023Piper SandlerUnderweightInitialise
Feb 28, 2023RBC CapitalOutperformInitialise
Feb 28, 2023Cowen & Co.OutperformInitialise
Feb 28, 2023SVB LeerinkOutperformInitialise
Feb 28, 2023Loop Capital MarketsBuyInitialise
Apr 26, 2022Zacks Investment ResearchBuyUpgrade

Disc Medicine's last stock rating was published by Scotiabank on Nov 05, 2024. The company gave IRON a "Sector Outperform" rating, the same as its previous rate.

Disc Medicine Financial Forecast

Disc Medicine Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Disc Medicine's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IRON's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Disc Medicine EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict IRON's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Disc Medicine's previous annual EBITDA (undefined) of $NaN.

Disc Medicine Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-38.02M$-40.58M$-37.96M$-34.10M$-36.83M$-31.04M$-28.33M
High Forecast$-38.02M$-40.58M$-37.96M$-30.38M$-30.87M$-31.04M$-28.33M
Low Forecast$-38.02M$-40.58M$-37.96M$-37.20M$-49.46M$-31.04M$-28.33M
Surprise %-------

Disc Medicine's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IRON's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Disc Medicine SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Disc Medicine's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IRON last annual SG&A of $NaN (undefined).

Disc Medicine EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-1.27$-1.36$-1.27$-1.14$-1.23$-1.04$-1.10
High Forecast$-1.27$-1.36$-1.27$-1.01$-1.03$-1.04$-1.10
Low Forecast$-1.27$-1.36$-1.27$-1.24$-1.65$-1.04$-1.10
Surprise %-------

According to undefined Wall Street analysts, Disc Medicine's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IRON previous annual EPS of $NaN (undefined).

Disc Medicine Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BMEABiomea Fusion$4.64$23.33402.80%Buy
ANEBAnebulo Pharmaceuticals$1.31$6.00358.02%Buy
OLMAOlema Pharmaceuticals$6.14$27.00339.74%Buy
LRMRLarimar Therapeutics$4.32$17.00293.52%Buy
ABOSAcumen Pharmaceuticals$1.96$7.00257.14%Buy
GPCRStructure Therapeutics$31.48$99.00214.49%Buy
ACRVAcrivon Therapeutics$7.21$22.50212.07%Buy
ANABAnaptysBio$15.99$49.83211.63%Buy
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
FENCFennec Pharmaceuticals$6.07$15.75159.47%Buy
MLYSMineralys Therapeutics$12.35$30.00142.91%Buy
ADAGAdagene$2.10$5.00138.10%Buy
AMLXAmylyx Pharmaceuticals$4.28$8.2592.76%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
MLTXMoonLake Immunotherapeutics$56.30$100.0077.62%Buy
CNTACentessa Pharmaceuticals$17.60$23.2532.10%Buy
CRNXCrinetics Pharmaceuticals$55.37$69.0024.62%Buy
IRONDisc Medicine$65.00$77.6719.49%Buy
TRDAEntrada Therapeutics$18.45$20.008.40%Buy

IRON Forecast FAQ

Is Disc Medicine a good buy?

Yes, according to 12 Wall Street analysts, Disc Medicine (IRON) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 91.67% of IRON's total ratings.

What is IRON's price target?

Disc Medicine (IRON) average price target is $77.67 with a range of $50 to $112, implying a 20.42% from its last price of $64.5. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Disc Medicine stock go up soon?

According to Wall Street analysts' prediction for IRON stock, the company can go up by 20.42% (from the last price of $64.5 to the average price target of $77.67), up by 73.64% based on the highest stock price target, and down by -22.48% based on the lowest stock price target.

Can Disc Medicine stock reach $100?

IRON's highest twelve months analyst stock price target of $112 supports the claim that Disc Medicine can reach $100 in the near future.

What are Disc Medicine's analysts' financial forecasts?

Disc Medicine's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-96.198M (high $-90.235M, low $-109M), average SG&A $0 (high $0, low $0), and average EPS is $-3.372 (high $-3.172, low $-3.793). IRON's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-151M (high $-147M, low $-154M), average SG&A $0 (high $0, low $0), and average EPS is $-5.033 (high $-4.909, low $-5.136).